Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
|
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Drug Repurposing for Triple-Negative Breast Cancer
    Avalos-Moreno, Marta
    Lopez-Tejada, Araceli
    Blaya-Canovas, Jose L.
    Cara-Lupianez, Francisca E.
    Gonzalez-Gonzalez, Adrian
    Lorente, Jose A.
    Sanchez-Rovira, Pedro
    Granados-Principal, Sergio
    JOURNAL OF PERSONALIZED MEDICINE, 2020, 10 (04): : 1 - 34
  • [22] Developing combination therapies with biologics in triple-negative breast cancer
    Gaudio, Gilda
    Martino, Enzo
    Pellizzari, Gloria
    Cavallone, Matteo
    Castellano, Grazia
    Omar, Abeid
    Katselashvili, Lika
    Trapani, Dario
    Curigliano, Giuseppe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (10) : 1075 - 1094
  • [23] A review of current progress in triple-negative breast cancer therapy
    Shen, Meiying
    Pan, Huawen
    Chen, Yuxia
    Xu, Yu Hang
    Yang, Weixiong
    Wu, Zhaojun
    OPEN MEDICINE, 2020, 15 (01): : 1143 - 1149
  • [24] Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon
    Khadela, Avinash
    Soni, Shruti
    Shah, Aayushi C.
    Pandya, Aanshi J.
    Megha, Kaivalya
    Kothari, Nirjari
    Avinash, C. B.
    MEDICAL ONCOLOGY, 2022, 40 (01)
  • [25] A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
    Liu, Yuetong
    Hong, Ge
    Mao, Lina
    Su, Zhe
    Liu, Tianjun
    Liu, Hong
    MOLECULES, 2023, 28 (09):
  • [26] Triple-Negative Breast Cancer: Not Entirely Negative
    Leone, Jose Pablo
    Puhalla, Shannon
    ONCOLOGY-NEW YORK, 2013, 27 (09): : 856 - +
  • [27] Novel molecular insights into pyroptosis in triple-negative breast cancer prognosis and immunotherapy
    Yu, Bin
    Luo, Junjie
    Yang, Yifei
    Zhen, Ke
    Shen, Binjie
    JOURNAL OF GENE MEDICINE, 2024, 26 (01)
  • [28] Triple-negative breast cancer: Novel therapies and new directions
    Pal, Sumanta Kumar
    Mortimer, Joanne
    MATURITAS, 2009, 63 (04) : 269 - 274
  • [29] Novel prognostic markers for patients with triple-negative breast cancer
    Zhou, Ling
    Li, Ke
    Luo, Yanli
    Tian, Ling
    Wang, Min
    Li, Chuanyuan
    Huang, Qian
    HUMAN PATHOLOGY, 2013, 44 (10) : 2180 - 2187
  • [30] Systemic treatment in triple-negative breast cancer patients - standard and novel approaches
    Debska-Szmich, Sylwia
    Potemski, Piotr
    ONCOLOGY IN CLINICAL PRACTICE, 2024, 20 (06): : 399 - 414
12345